Background. Mother-to-child transmission of hepatitis B can be prevented with vaccination and screening. Foreign-born women living in the United States may have lower vaccination coverage and greater lifetime exposure to hepatitis B virus than US-born women. This study compares self-reported hepatitis B vaccination and screening between US-born and foreign-born women of reproductive age and examines predictors.
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) leads to acute infection in up to 90% of infants born to infected mothers [1] . About 80% of HBV-infected women who gave birth in the United States during 2006 were born in other countries [2] . Because global provisions for hepatitis B vaccination and screening vary, domestic strategies addressing foreign-born women of reproductive age are needed to prevent MTCT of HBV.
Some countries implemented universal infant vaccination strategies soon after the vaccine was developed in 1981 [3] , but it was not until 1991 that the United States adopted such a strategy [4, 5] . In fact, few countries implemented national hepatitis B infant vaccination strategies early enough to ensure protection among women who are currently of reproductive age [6] . As an example, 1997 infant vaccination coverage was highest in the Eastern Mediterranean (35%), Americas (28%), and Europe (23%); coverage estimates were lower in Southeast Asia (10%), the Western Pacific (9%), and Africa (4%) [6] .
In the United States, women of reproductive age who seek medical care are not universally offered hepatitis B vaccine. Some women who were not vaccinated in infancy may have been vaccinated as adults or adolescents through catch-up vaccination and risk-based vaccination policies. Vaccination recommendations for high-risk adults were issued in 1982 soon after the vaccine first became available in the United States [7, 8] . Late in the 1990s, "catch-up" vaccinations were recommended for adolescents who were not vaccinated previously [5] . The American College of Obstetricians and Gynecologists (ACOG) considers vaccination during pregnancy to be safe and recommends specifically that susceptible pregnant women who are at risk for HBV infection should be vaccinated [1, 9] . Internationally, the World Health Organization recommends vaccinations for high-risk adults and adolescents who have not yet been vaccinated; however, implementation of this recommendation varies globally [10] , and US citizenship requires hepatitis B vaccination only for persons younger than 19 years [11] . Three doses of the vaccine are recommended for full immunity, and 25% of US adults aged ≥19 years had received ≥3 doses in 2015 [12] .
Ideally, all women of reproductive age who reside in the United States would have been previously vaccinated for hepatitis B, nearly eliminating the risk of MTCT. Although the Advisory Committee for Immunization Practices recognizes that persons born in or emigrating from HBV-endemic countries are at higher risk of having chronic HBV infection than the general US population [4, 7] , US hepatitis B vaccination recommendations do not specifically address vaccination of this population, and screening is not required for immigrants or refugees at the time of entry [13] . Hence, vaccination and screening for HBV among women of reproductive age are crucial to eventually eliminate MTCT. The ACOG first issued a practice bulletin recommending routine prenatal screening of all pregnant women in 2007 and has since reaffirmed this recommendation [1] .
All persons in the United States who were born in regions of the world with moderate or high HBV rates should be screened based on US Centers for Disease Control and Prevention (CDC) guidelines [14, 15] . West Africa has the highest prevalence of hepatitis B (≥8%), and many African regions have high-intermediate prevalence (5%-7%) [16] . Asia also contains many regions with high-intermediate prevalence, with some areas of low-intermediate prevalence (2%-4%) in the Indian subcontinent, Middle East, and high-income countries on the Pacific [16] . In addition, Europe and the Caribbean contain some areas of low-intermediate prevalence [16] . In this analysis, US nationwide survey data from a 3-year period were pooled to (1) determine whether hepatitis B vaccination and screening prevalence differ between US-born and foreign-born women of reproductive age and (2) examine factors that may contribute to these differences.
METHODS

Data Source
We analyzed public-use data from the 2013-2015 National Health Interview Survey (NHIS), conducted annually by the CDC's National Center for Health Statistics [17] . The NHIS is a cross-sectional in-person survey that collects health and healthcare information from the civilian noninstitutionalized US population, using a complex multistage sampling design. Face-to-face interviews are conducted by the US Census Bureau in respondents' homes. For this analysis, we merged family and sample adult data (information from 1 randomly selected adult within each family), to construct an analytic data set with selected adults' responses to questions about hepatitis B vaccination and screening history and individual and family characteristics.
Final response rates for the family component ranged from 69.3% in 2013 to 74.9% in 2015, and sample adult final response rates ranged from 55.2% in 2013 to 61.2% in 2015. Data collection for the NHIS was approved by the National Center for Health Statistics Research Ethics Review Board. Analysis of deidentified data from the survey is exempt from the federal regulations for the protection of human research participants [17] . More detailed information on survey design for NHIS is available from the survey documentation [18] .
Measures
In 2013-2015, the NHIS included questions assessing lifetime prevalence of hepatitis B vaccination and screening. Respondents were considered vaccinated if they reported receiving ≥3 doses of the hepatitis B vaccine in their lifetime and were considered screened if they reported undergoing a blood test for hepatitis B in their lifetime. Women may have been vaccinated or screened within the United States or any other country where they once lived; no further questions are included in the survey to elucidate when or where services took place.
The country of birth was recorded as the world region of birth for confidentiality in the public use file. Number of years in the United States, ability to speak English, and citizenship status were all self-reported by adults born outside the United States.
Sociodemographic characteristics included 3 birth-year cohorts categorized according to Advisory Committee for Immunization Practices vaccine recommendations (Table 1 ). Race/ethnicity may be self-reported, reported by a family member, imputed from data on other household members, or imputed from data on members of other households within a small geographic area. Although women born in Puerto Rico are by definition US born, some women may have self-reported being foreign born and having Puerto Rican ethnicity. We present what was reported by the respondent. Participants were categorized by education, marital status, and current pregnancy status. The federal poverty level (FPL) is based on reported and imputed family income and family size, using the US Census Bureau's poverty thresholds. Healthcare use characteristics included insurance coverage, past-year healthcare provider visit, and usual place for medical care.
Statistical Analyses
To obtain stable estimates of women aged 18-44 years who were born in specific world regions, we pooled 3 years of data from the NHIS (2013) (2014) (2015) . Women whose foreign-born status was unknown (n = 15) were excluded. The survey weights were adjusted for pooling by dividing each weight by the number of years of data pooled (ie, the adjusted survey weight equals the original survey weight divided by 3). Variance estimation was based on the Taylor series linearization method for clustered data, and 95% confidence intervals were reported [19] .
Estimates with an unweighted denominator of ≥100, unweighted numerator of ≥10, and relative standard error < 30% were considered statistically stable. We used t tests to determine demographic differences and differences in healthcare use between US-born and foreign-born women where χ 2 tests of independence had statistically significant results (P ≤ .05 or type I error rate of .05%). All comparisons described in the results had statistically significant results (t test, P ≤ .05). Unadjusted associations of demographic characteristics and healthcare use with hepatitis B vaccination and screening prevalence were tested for statistical significance using trend tests for ordinal categorical variables and χ 2 tests for other categorical variables.
The Cochran-Mantel-Haenszel test was used to determine whether the overall difference in vaccination and screening prevalence between US-born and foreign-born women persisted after consideration for each demographic and healthcare use variable. Among foreign-born women, χ 2 tests were used to assess unadjusted associations of vaccination and screening prevalence with world region of birth, number of years in the United States, ability to speak English, and US citizenship. Data management was conducted using SAS software (version 9.4; SAS Institute). All analyses were conducted using SUDAAN software (version 11.0.1; RTI International), and accounted for the multistage, clustered sampling design, unequal probabilities of selection and nonresponse, and poststratification to the US population.
RESULTS
After the total adult sample (n = 104 926) was limited to female respondents aged 18-44 years (n = 24 231) and women with unknown foreign-born status were excluded, the final sample Table 2 ). Foreign-born women were more likely to be married and to live in families with an income <200% FPL. An estimated 1 in 5 US women of reproductive age in 2013-2015 (20.1%) were born outside the United States ( Table 2) . Most of them (68.0%) had lived in the United States for ≥10 years, and 41.2% were US citizens. Fewer foreign-born women were insured than US-born women (68.2% vs 86.4%, respectively) and fewer foreign-born women had visited a healthcare provider in the past year (74.4% vs 85.3%, respectively).
Vaccination
Overall, 40.9% of US-born women reported having received ≥3 doses of hepatitis B vaccine in their lifetime, compared with 27.3% of foreign-born women (Table 3) . Foreign-born women reported significantly lower vaccination coverage than US-born women, regardless of sociodemographic characteristics examined, with the exception of certain racial/ethnic groups.
Among foreign-born women, vaccination coverage was lowest for those born in Mexico, Central America, or the Caribbean islands (18.4%), followed by South America (25.3%) and the Indian subcontinent (31.7%; Table 3 ). Vaccination coverage was also low among women who had been in the United States for 10 to <15 years (23.7%) and those who were not US citizens (23.8%).
Age cohort effects on hepatitis B vaccination coverage were more pronounced for US-born than for foreign-born women (Figure 1 ). Vaccination coverage was higher for women born after infant vaccination recommendations went into effect b Records indicating a response of "don't know" or a missing response for hepatitis B screening (n = 1884; 7.8%) or vaccination (n = 2197; 9.1%) were excluded for each measure.
c Odds ratio for US-born versus foreign-born women.
d Breslow-Day homogeneity of odds ratios, Wald F statistic.
e Estimates differ significantly different between foreign-born and US-born women (t test, P < .05).
f Birth origin was associated with vaccination outcome, independent of stratification variable (Cochran-Mantel-Haenszel test, P < .05).
g Test for trend for both outcomes in both US-born and foreign-born women, P < .05.
h Birth origin was associated with both vaccination and screening outcomes, independent of stratification variable (Cochran-Mantel-Haenszel test, P < .05).
i Owing to limited sample size (n < 100), the Middle East and Russia/former Union of Soviet Socialist Republics areas are not shown. Definitions for world regions are available online [20] . j Characteristic associated with outcome (both vaccination and screening) among foreign-born women (χ 2 test, P < .05).
k Test for trend for HBV screening in foreign-born women, P < .05. l Test for trend for both outcomes in foreign-born women, P < .05. in 1991 for US-born women. Only modest improvements occurred for foreign-born women born after 1990.
Screening
The prevalence of screening history for HBV infection at any age was somewhat higher for US-born than for foreign-born women (31.9% vs 28.5%, respectively; Table 3 ). The lowest screening prevalence occurred among foreign-born Hispanic or Latina Mexican (21.0%) and Puerto Rican (21.9%) women. Higher screening prevalence was associated with higher education for both US-born and foreign-born women, and in fact, foreign-born women who had a bachelor's or graduate degree were more likely to have been screened than their US-born counterparts (38.0% vs 32.5%, respectively). Birth origin was not associated with screening independently of race/ethnicity or education. Poverty had contradictory effects among US-born versus foreign-born women, with respect to the percentage of women screened (Table 3 ). Among US-born women, screening was most prevalent among women living at <100% FPL, whereas among foreign-born women, screening was most prevalent among women living at ≥400% FPL, and higher than among their US-born counterparts in the same income category (38.4% vs 31.1%, respectively). Regardless of birth origin, women who had never married had similar (low) screening prevalences. Only 33.2% of currently pregnant foreign-born women had been screened, compared with 47.8% of US-born pregnant women. Birth origin was associated with screening independent of FPL, marital status, current pregnancy, insured status, past-year provider visit, and usual place for care.
Among foreign-born women, history of HBV screening prevalence was lowest for those born in Mexico, Central America, or the Caribbean islands (22.6%) and highest for those born in Europe (37.2%) or Africa (36.3%). Screening prevalence was associated with the number of years living in the United States, ability to speak English, and US citizenship.
Age cohort effects on history of HBV screening were evident for US-born women (test for age trend, P ≤ .05) but not foreign-born women (data not shown). For US-born women, the 2 older cohorts were more likely to have been screened (34.8% of women born in 1969-1980 and 35.4% born in [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] than the cohort born after 1990 (22.3%; P ≤ .05 for both comparisons). Screening prevalence was similar for foreign-born and US-born women born in 1991-1997 (22.4% vs 22.3%). Foreign-born women born in 1969-1980 had lower screening prevalence than their US-born counterparts (28.9% vs 34.8%, respectively; P ≤ .05), as was the case for those born in 1981-1990 (30.5% vs 35.4%; P ≤ .05).
Women Who Visited a Healthcare Provider
Among women of reproductive age who had visited a healthcare provider in the past year, disparities by world region of birth remained for hepatitis B vaccination prevalence (Figure 2 ). Women born in Mexico, Central America, or the Caribbean islands were less likely to have been screened for HBV (26.7%; 95% confidence interval, 24.2%-29.4%) than those born in the United States (33.1%; 32.0%-34.1%). Among pregnant women specifically, about half of US-born women who had seen a physician in the past year reported a history of hepatitis B screening (48.8%); this dropped to 29.7% for those born in Mexico, Central America, or the Caribbean islands (data not shown). 
DISCUSSION
This study addressed hepatitis B vaccination and screening among women of reproductive age living in the United States, for whom MTCT can result in US infants being infected with hepatitis B at birth [2, 10] . Hepatitis B vaccination and screening coverage rates were significantly lower among foreign-born than among US-born women, with only approximately one-fourth of foreign-born women reporting a history of receiving 3 doses of hepatitis B vaccine and screening. These findings can be used to evaluate US vaccination and screening recommendations, and further develop public health strategies to target hepatitis B screening and vaccination coverage among women of reproductive age. This is critical to eliminating MTCT of hepatitis B in the United States.
For US-born women, self-reported hepatitis B vaccination status varied by birth cohort because universal vaccination recommendations were implemented in phases [5] . Birth dose recommendations put into place in 1991 had a significant effect on vaccination coverage for women born in 1991-1997; however, vaccination coverage for the 1969-1980 birth cohort remains low.
In contrast with US-born women, each consecutive cohort of foreign-born women experienced minimal increases in vaccination coverage. Overall, vaccination coverage among reproductive-aged women was 33% lower for foreign-born than for US-born women. Despite this pattern, foreign-born women of reproductive age in the United States are not currently targeted for hepatitis B vaccination [21] . Better vaccination coverage could decrease the need for the intense follow-up and resources to treat infected women and their infants. Among pregnant women specifically, vaccination coverage was 39% lower for foreign-born than for US-born women. . Vaccination coverage rates differed significantly (P < .05) between US-born women and those born in Mexico, Central America, the Caribbean islands, the Indian subcontinent, and South America. Screening prevalence differed significantly (P < .05) between US-born women and those born in Mexico, Central America, and the Caribbean islands.
Screening prevalence was expected to approach 100% among pregnant women because of ACOG guidelines [1] ; however, the data from this study indicate either that clinical practice fell short or that women are not aware that they have been screened for hepatitis B. Only one-third of foreign-born pregnant women and one-half of US-born pregnant women reported undergoing screening, indicating a potential need for provider and/or patient education around the importance of knowing their hepatitis B infection status.
Overall, foreign-born women of reproductive age were no more likely than US-born women to be screened for hepatitis B, although the prevalence was slightly improved for every world region except Mexico, Central America, and the Caribbean islands. This finding is consistent with the distribution of HBVendemic countries, and a more refined geographic variable may show higher correlation between screening prevalence and endemicity. Still, screening rates are low, including in the regions with highest HBV endemicity (>8%). To identify all those who require treatment, providers should bear in mind the latent nature of chronic hepatitis B [22] and consider screening even for foreign-born women who have lived in the United States for many years. Not surprisingly, our data also show poverty and lack of access to care as major determining factors in disparities among foreign-born women. Thus, provider education may not be enough to address the issue; additional efforts to improve access to healthcare services for immigrant women will be necessary.
Vaccination coverage was low for women born in Mexico and other parts of Central America, South America, the Caribbean islands, and the Indian subcontinent. Among foreign-born women, about one-third of women of reproductive age immigrating in the past 5 years had been vaccinated; however, vaccination coverage dropped for those who had immigrated less recently. Healthcare services routinely provided to illegal immigrants, including at community health centers, free clinics, and urgent care settings, may consider incorporating policies that address hepatitis B vaccination for reproductive-aged women [23] .
Several limitations should be considered in this study. Misclassification may occur if women have a difficult time recalling specific clinical care or if they were screened or vaccinated without being specifically and thoroughly informed by providers. Particularly for foreign-born women, the ability to speak English, language interpretation, and proxy reports may have influenced reporting. Each world region and ethnicity category, as defined by the NHIS, may contain a mix of high/low endemicity, and vaccination policies vary by country; therefore, only general conclusions can be made. For example, Cuba has low endemicity, whereas the Dominican Republic has low-intermediate endemicity and Haiti has high endemicity [24] . Finally, and importantly, women considered foreign born in our study could include naturalized US citizens, lawful permanent residents (immigrants), temporary migrants (such as foreign students), humanitarian migrants (such as refugees and asylees), and unauthorized migrants [25] . Generalizations for such a heterogeneous population may be problematic, and as a household-based survey NHIS may not account for women who do not have a stable and established residence.
In conclusion, women of reproductive age who migrated to the United States could benefit from targeted vaccination programs. In addition, public health screening efforts for hepatitis B in the United States may require further assessment, especially for women born in world regions with moderate or high hepatitis B endemicity. Until HBV screening and vaccination among women of childbearing ages are addressed, MTCT of hepatitis B will probably continue to occur in the United States. 
